PET Pharm Biotech Co., Ltd.

As of June 30, 2026, PET Pharm Biotech Co., Ltd. carries a market capitalization of 2.90B, placing it among publicly traded companies globally. Its enterprise value stands at 2.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PET Pharm Biotech Co., Ltd. has 58.09M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PET Pharm Biotech Co., Ltd. maintains a current ratio of 6.03, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, PET Pharm Biotech Co., Ltd.'s stock has declined approximately 35.19% over the past 52 weeks. The 50-day moving average sits at 55.08, while the 200-day moving average is 55.49.

As of June 30, 2026, PET Pharm Biotech Co., Ltd. holds 410.09M in cash and equivalents against 108.15M in total debt, resulting in a net debt position of -194.27M. Total book value stands at 1.17B, with working capital of 405.60M providing operational flexibility.

PET Pharm Biotech Co., Ltd.'s most recent stock split took place on July 20, 2026 with a 200:203 split ratio.